How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Press’ post set off a firestorm of controversy within the Haskell community, which is small but vocal, and likely felt the ...

Julie Young is an experienced financial writer and editor. She specializes in financial analysis in capital planning and investment management. Investopedia / Mira Norian A monopsony features a single ...